On April 24, 2021, the Conference of Western Tour of Pediatric Clinical Practice Guidelines and the Workshop on Clinical Practice Guideline Development Strategies of the Pediatric Branch of the Chinese Medical Association were successfully held in Yinchuan, China. The conference was chaired by Prof. Jiang Yuwu, Vice Chairman of the Pediatrics Branch of the Chinese Medical Association, and moderated by Prof. Zhang Chongfan, Associate Editor-in-Chief of the Chinese Journal of Evidence-Based Pediatrics. With the theme of "Pursuing Excellence, Leading the Future", the conference invited renowned experts from China, Canada, and Colombia in clinical epidemiology, clinical guideline development methodology, and pediatrics to discuss the methodology and development of clinical practice guidelines in the field of pediatrics in China with young scholars.
On 17-18 April, the 2021 National Clinical Practice Guidelines (CPGs) Methodology Training Course was successfully held in Beijing, which was co-organized with the support of the Lanzhou University, Affiliate of the Cochrane China Network, together with Chinese Medical Association Publishing House and the WHO Collaborating Centre for Guidelines Implementation and Knowledge Translation. Sixty-six clinicians and researchers from 12 provinces and municipalities across China participated in the entire two-day training course.
In February 2021, Chinese guidelines for diagnosis and treatment of diabetic kidney disease (Registration number: IPGRP-2021CN035) were published online by the Chinese Society of Nephrology in the Chinese Journal of Nephrology. The guideline is based on domestic and international expert consensus and integrates the clinical experience of Chinese nephrologists. This guideline contains the diagnosis of diabetic kidney disease (DKD), renal pathology biopsy, treatment and management, management of complications, and rational application of commonly used drugs. The expert group has referred to the international guideline format in the preparation process based on the principles of rigor, conciseness, and authority. The guidelines reflect new trends and perspectives in the treatment of DKD and are of great value in further strengthening the understanding of DKD, standardizing the treatment system, formulating reasonable treatment principles, guiding the precise use of drugs, delaying the progression of kidney disease. It will improve the life quality of patients and could be used by physicians for reference in clinical work.
The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help to improve the reporting quality of the systematic reviews. The first edition of the PRISMA statement has been published over 10 years. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline.
In January 2021，Runsheng Xie published an article in Pharmacological Research entitled The RIGHT Extension Statement for Traditional Chinese Medicine: Development, Recommendations, and Explanation. Nowadays, the number of traditional Chinese medicine (TCM) guidelines is constantly increasing, but its reporting quality remains unsatisfactory. The group hopes that the RIGHT-TCM may assist TCM guideline developers in reporting guidelines, support journal editors and peer reviewers when considering TCM guideline reports, and help health care practitioners understand and implement a TCM guideline.